* Guilford Pharmaceuticals Inc., of Baltimore, concludedan exclusive marketing, supply and distributionagreement for the Gliadel wafer in Scandinavia withOrion-Farmos Corp. Guilford will sell Gliadel to Orionand receive milestone and other payments.
* InSite Vision Inc., of Alameda, Calif., which isdeveloping eyedrop-based drug delivery technology, isrestructuring to conserve cash. About half of thecompany's 70 employees were let go, and self-fundedproduct development will be reduced substantially.
* Integra LifeSciences Corp., of Plainsboro, N.J.,received FDA approval to export its Integra Artifical Skinto Denmark. The product, which is under review by theFDA for marketing in the U.S., is used to restorefunctional dermal tissue in critically burned patients.
* Pharmacia AB, of Stockholm, Sweden, and The UpjohnCo., of Kalamazoo, Mich., completed their merger,becoming the world's ninth largest pharmaceuticalcompany with sales of nearly $7 billion in 1994.
* Sepracor Inc., of Marlborough, Mass., priced its $75million offering of convertible subordinated debenturesdue 2002. They will have an annual coupon of 7 percent,won't be redeemable for three years, and will beconvertible into common stock at $19.68 per share.
* Sequus Pharmaceuticals Inc., of Menlo Park, Calif.,said preliminary Phase II results showed Doxil produceda response in 25 percent of 20 ovarian cancer patientsevaluated. All had failed prior chemotherapy treatment. APhase III study is being planned.
* Teva Pharmaceutical Industries Ltd., of Jerusalem,purchased 78 percent of Hungarian-based BiogalPharmaceutical Co. Ltd. for $26 million. Biogal's 1994net income was $5.4 million on sales of $102 million.Teva said the acquisition will assist it in launchingCopaxone, the company's multiple sclerosis treatment, inHungary.
* Transcend Therapeutics Inc., of Cambridge, Mass.,began a Phase I/II trial of Procysteine for dermatitis.Procysteine is designed to replenish glutathione, whichprotects the body from reactive oxygen species.
* Trinity Biotech, of Dublin, Ireland, raised $3 million inan offering to European institutional investors.
(c) 1997 American Health Consultants. All rights reserved.